Evec
Evec is a biotechnology company dedicated to developing and commercializing high-quality human antibodies for therapeutic and diagnostic applications. Founded in 2003 in Hokkaido, Japan, the company leverages its proprietary antibody production technology to contribute to global healthcare by creating innovative antibody-based medicines and diagnostic tools. Evec aims to be a partner for pharmaceutical companies and research institutions worldwide, focusing on antibody manufacturing, open innovation, and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Patents
Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
US-8679502-B2
View DetailsMonoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
US-8492529-B2
View DetailsHuman monoclonal antibody binding to hGM-CSF and its antigen binding portion
US-7935795-B2
View Details
Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
US-8679502-B2
View DetailsMonoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
US-8492529-B2
View DetailsHuman monoclonal antibody binding to hGM-CSF and its antigen binding portion
US-7935795-B2
View DetailsProducts
Research-use fully human monoclonal antibodies (catalog)
Catalog/stocked fully human monoclonal antibodies with confirmed high affinity and neutralization activity for use as assay reagents, positive controls, and research reagents; offered via external distributor.
Research-use fully human monoclonal antibodies (catalog)
Catalog/stocked fully human monoclonal antibodies with confirmed high affinity and neutralization activity for use as assay reagents, positive controls, and research reagents; offered via external distributor.
Services
Contract or collaborative projects to generate target-specific fully human antibodies from supplied or collected human blood specimens, including screening, cloning and characterization; IP and licensing arrangements negotiable.
Development of detection antibodies optimized for diagnostic and test-kit applications, with emphasis on high antigen affinity and mitigation of HAMA-related false results; intended to be co-developed or integrated with established kit manufacturers.
Joint research programs combining external disease- or target-specific expertise with antibody discovery technology to advance leads toward licensing and commercialization.
Provision of produced fully human monoclonal antibodies for use in research assays, neutralization testing and as positive controls, distributed through external distributors.
Contract or collaborative projects to generate target-specific fully human antibodies from supplied or collected human blood specimens, including screening, cloning and characterization; IP and licensing arrangements negotiable.
Development of detection antibodies optimized for diagnostic and test-kit applications, with emphasis on high antigen affinity and mitigation of HAMA-related false results; intended to be co-developed or integrated with established kit manufacturers.
Joint research programs combining external disease- or target-specific expertise with antibody discovery technology to advance leads toward licensing and commercialization.
Provision of produced fully human monoclonal antibodies for use in research assays, neutralization testing and as positive controls, distributed through external distributors.
Expertise Areas
- Human monoclonal antibody discovery
- Antibody screening and characterization
- Diagnostic antibody development for in vitro diagnostics
- Collaborative research and licensing with pharma and academia
Key Technologies
- EBV-mediated B cell immortalization
- Antibody gene cloning and recombinant expression
- ELISA
- Flow cytometry
News & Updates
Evec participated in BioJapan 2023 to showcase its latest antibody technologies.
An article highlighting Evec's proprietary technology for producing safe and effective human antibodies.
Evec signed its first international contract with Bayer Ingelheim in 2008, demonstrating its high-quality antibody production capabilities.
Evec participated in BioJapan 2023 to showcase its latest antibody technologies.
An article highlighting Evec's proprietary technology for producing safe and effective human antibodies.
Evec signed its first international contract with Bayer Ingelheim in 2008, demonstrating its high-quality antibody production capabilities.